Dow Jones

42,732.13

0.80%

Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.

Regístrate

CVM

Cel Sci (CVM)

Cel Sci Corporation New

Fecha:

Regulatory News

Text Search:

Ordernar por:

Non-Regulatory News

Showing the most relevant articles for your search:AMEX:CVM

1 2 3 4 5 6 7 Próxima >

Fecha	Hora	Fuente	Título	Símbolo	Compañía
03/01/2025	16:25	Edgar (US Regulatory)	Form 424B3 - Prospectus [Rule 424(b)(3)]	AMEX:CVM	Cel Sci Corporation New
02/01/2025	13:25	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	AMEX:CVM	Cel Sci Corporation New
31/12/2024	15:15	Edgar (US Regulatory)	Form 8-K - Current report	AMEX:CVM	Cel Sci Corporation New
31/12/2024	15:05	Business Wire	CEL-SCI Announces Closing of $5 Million Offering	AMEX:CVM	Cel Sci Corporation New
30/12/2024	16:05	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	AMEX:CVM	Cel Sci Corporation New
30/12/2024	15:16	Edgar (US Regulatory)	Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405	AMEX:CVM	Cel Sci Corporation New
29/12/2024	19:41	Business Wire	CEL-SCI Announces Pricing of $5 Million Public Offering	AMEX:CVM	Cel Sci Corporation New
27/12/2024	16:05	Business Wire	CEL-SCI Announces Proposed Public Offering of Common Stock	AMEX:CVM	Cel Sci Corporation New
12/12/2024	08:15	Business Wire	CEL-SCI Highlights Biological Rationale for the Use of Multikine in the Confirmatory Registration Head and Neck Cancer Study	AMEX:CVM	Cel Sci Corporation New
07/11/2024	23:15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	AMEX:CVM	Cel Sci Corporation New
07/11/2024	07:15	Business Wire	U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025	AMEX:CVM	Cel Sci Corporation New
30/10/2024	16:21	Edgar (US Regulatory)	Form S-3/A - Registration statement under Securities Act of 1933: [Amend]	AMEX:CVM	Cel Sci Corporation New
25/10/2024	16:17	Edgar (US Regulatory)	Form S-3 - Registration statement under Securities Act of 1933	AMEX:CVM	Cel Sci Corporation New
22/10/2024	08:15	Business Wire	FDA’s Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI’s Multikine® to Address Major Treatment Gap for PD-L1 Negative Cancer Patients	AMEX:CVM	Cel Sci Corporation New
11/10/2024	16:00	Edgar (US Regulatory)	Form POS AM - Post-Effective amendments for registration statement	AMEX:CVM	Cel Sci Corporation New
10/10/2024	15:05	Edgar (US Regulatory)	Form AW - Amendment Withdrawal Request	AMEX:CVM	Cel Sci Corporation New
01/10/2024	05:00	Business Wire	CEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine® in Head and Neck Cancer	AMEX:CVM	Cel Sci Corporation New
16/09/2024	06:30	Business Wire	CEL-SCI’s Multikine® Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and Radiation	AMEX:CVM	Cel Sci Corporation New
10/09/2024	08:32	Business Wire	CEL-SCI to Present New Data for Multikine® Head & Neck Cancer Immunotherapy at the European Society for Medical Oncology 2024 Congress	AMEX:CVM	Cel Sci Corporation New
04/09/2024	08:00	Business Wire	The UK’s Medicines & Healthcare Products Regulatory Agency Grants CEL-SCI a Pediatric Waiver, Bringing Multikine® One Step Closer to Future Marketing Clearance	AMEX:CVM	Cel Sci Corporation New
30/08/2024	15:32	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	AMEX:CVM	Cel Sci Corporation New
15/08/2024	07:00	Business Wire	CEL-SCI Corporation Reports Third Quarter Fiscal 2024 Financial Results	AMEX:CVM	Cel Sci Corporation New
14/08/2024	15:27	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	AMEX:CVM	Cel Sci Corporation New
29/07/2024	15:05	Business Wire	CEL-SCI Announces Closing of $10.8 Million Offering	AMEX:CVM	Cel Sci Corporation New
26/07/2024	10:52	Business Wire	CEL-SCI Announces Pricing of $10.8 Million Offering	AMEX:CVM	Cel Sci Corporation New
26/07/2024	07:23	Business Wire	CEL-SCI’s Phase 3 Population Analysis for Upcoming Confirmatory Registration Study in Head & Neck Cancer Demonstrates Well Balanced Patient Population, Confidence in Clinical Results	AMEX:CVM	Cel Sci Corporation New
08/07/2024	08:15	Business Wire	CEL-SCI Appoints Robert Watson as Chairperson of the Board	AMEX:CVM	Cel Sci Corporation New
18/06/2024	07:00	Business Wire	CEL-SCI Presents Head & Neck Cancer Data at Iddst Annual Congress in Budapest: Risk of Death Cut in Half for Patients Treated With Multikine in the Target Population	AMEX:CVM	Cel Sci Corporation New
06/06/2024	06:00	Business Wire	Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor	AMEX:CVM	Cel Sci Corporation New
16/05/2024	08:00	Business Wire	CEL-SCI Corporation Reports Second Quarter Fiscal 2024 Financial Results	AMEX:CVM	Cel Sci Corporation New